Tabbetha Dobbins

Director at Sentrimed

Capital raised by Sentrimed

$250K+$250K latest round

1 Form D filing · first filed May 2026 · Mullica Hill, NJ

Career

1 company on file · founded 2023

SentrimedBiotech · Mullica Hill, NJsince 2023

Director

Listed on Sentrimed's Form D filings

via EDGAR · Form D for Sentrimed1

DateCompanyFormAmountRole on filing

May 8, 2026SentrimedForm D+$250K—

Form DMay 8, 2026 · Sentrimed+$250Knot a signer

Last filing May 8, 2026

Tabbetha Dobbins is on file as Director at Sentrimed in Mullica Hill, NJ. Sentrimed has 1 Form D filing on record, $250K raised in total.

Sentrimed · 1

Sentrimed · 1

MASL (lenipagrusin alfa)Oncology drug candidate

An orally administered small-molecule podoplanin (PDPN) inhibitor in clinical development, with head and neck cancer as the initial indication.